par Van Caloen, Gabrielle;Schmitz, Sandra;El Baroudi, Mariama;Caignet, Xavier;Pyr Dit Ruys, Sébastien;Roger, Pierre P.
;Vertommen, Didier;Machiels, Jean Pascal
Référence Molecular cancer therapeutics
Publication Publié, 2020-01

Référence Molecular cancer therapeutics
Publication Publié, 2020-01
Article révisé par les pairs
Résumé : | Cell cycle pathway impairments resulting in cyclin-dependent kinase (CDK) 4 and 6 activation are frequently observed in human papillomavirus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN). We investigated the activity of ribociclib, a CDK4/6 inhibitor, in SCCHN models with the aim of identifying predictive biomarkers of response. |